What type of drug is Alunbrig?
Alunbrig (brigatinib) is an anaplastic lymphoma kinase (ALK) inhibitor used for the treatment of patients with a certain type of lung cancer called ALK-positive non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastasized).
Alunbrig was first FDA approved in 2017 for patients with ALK-positive metastatic non-small cell lung cancer who had progressed on, or were intolerant to crizotinib. In May 2020, this indication was expanded to include Alunbrig as a first-line treatment option for ALK+ NSCLC. Alunbrig is manufactured by Takeda Pharmaceuticals.
About 85% of patients with lung cancer have non-small cell lung cancer (NSCLC), with 5% of those patients having a mutation in the ALK gene (ALK-positive).
What are the ALK inhibitors?
There are several ALK inhibitors approved by the FDA for the treatment of ALK+ NSCLC. They include:
- Alecensa (alectinib)
- Alunbrig (brigatinib)
- Lorbrena (lorlatinib)
- Xalkori (crizotinib)
- Zykadia (ceritinib)
Cancer that is “ALK-positive (ALK+)” means that certain genes have rearranged in your DNA leading to an “oncogene”. An oncogene can result in uncontrolled cancer cell replication. About 5% of patients with lung cancer have ALK-positive lung cancer.
Your doctor can order an FDA-approved test to determine if you have a mutation in the ALK gene and if you are ALK+. If so, you may be able to be treated with an ALK inhibitor.
The first ALK inhibitor to be FDA approved was crizotinib (Xalkori) in 2011. Acquired resistance to crizotinib is common (due to newly acquired mutations in the ALK gene), so the second-generation ALK inhibitors such as ceritinib (Zykadia), alectinib (Alecensa), brigatinib (Alunbrig) and Lorbrena (lorlatinib) were developed to help overcome crizotinib resistance.
This is not all the information you need to know about Alunbrig (brigatinib) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Alunbrig information here, and discuss this information and any questions you have with your doctor or other health care provider.
Related Questions
References
- Elliott J, Bai Z, Hsieh S-C et al. (2020) ALK inhibitors for nonsmall cell lung cancer: A systematic review and network meta-analysis. PLoS ONE 15(2):e0229179. https://doi.org/10.1371/journal.pone.0229179
- ALK Positive. What is ALK-positive lung cancer? Accessed Feb. 22, 2021 at https://www.alkpositive.org/what-is-alk
Read next
Related medical questions
- What type of lung cancer is Vizimpro used to treat?
- Why give Taxol (Paxel) before carboplatin?
- What is the difference between Opdivo and Keytruda?
- Pembrolizumab vs. nivolumab: How do they compare?
- What is Paxel called in the USA?
- How effective is Lumakras, what's the survival rate?
- How effective is Tabrecta?
- How does erlotinib work (mechanism of action)?
- How long can I take Gilotrif (afatinib) for?
- What is the difference between Mvasi and Avastin?
- How does Retevmo work?
- Will Tabrecta cure lung cancer?
- Are there cost-saving programs for Tecentriq?
- Is Tabrecta a chemotherapy drug?
- Can Tarceva (erlotinib) cure lung cancer?
- What is the mechanism of action for Alecensa (alectinib)?
- Is Gilotrif (afatinib) a chemotherapy drug?
- Is atezolizumab (Tecentriq) a chemotherapy or immunotherapy drug?
- How effective is atezolizumab (Tecentriq)?
- How effective is Alecensa for ALK-positive NSCLC?
- How long do you take Alecensa for?
- How do Exkivity and Rybrevant compare for NSCLC?
- How does Gilotrif (afatinib) work?
- How does pemetrexed work?
- How does Rybrevant work?
- How effective is Exkivity (mobocertinib) for NSCLC?
- Does atezolizumab (Tecentriq) cause hair loss?
- How long does it take for Xalkori to work?
- How to pronounce Xalkori?
- How does Alecensa work?
Drug information
- Alunbrig Information for Consumers
- Alunbrig prescribing info & package insert (for Health Professionals)
- Side Effects of Alunbrig (detailed)
Related support groups
- Alunbrig (1 questions, 3 members)
- Non-Small Cell Lung Cancer (52 questions, 70 members)
